Stargardt Disease Therapeutics Market Companies

Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others (Gildeuretinol), By Age Group (Children (Below 17 Years) and Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023

Code : CMI1314

Pages :167

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

These key players are investing heavily in research and development to find effective treatments and therapies for stargardt disease. Growing awareness and support from various organizations and government initiatives is expected to drive growth of the stargardt disease therapeutics market.

Global Stargardt Disease Therapeutics Market: Key Developments

In October 2022, ATP, a life sciences venture firm, is the most recent startup to make its debut with a novel approach to genetic editing. With US$ 50 million in funding, U.S.-based Ascidian Therapeutics claims that its RNA “exon editing” approach could match the durability of gene therapy while avoiding some of the risks that come with editing DNA. The platform is designed to correct for mutations in exons,the regions of DNA that contain information needed to make proteins

Global Stargardt Disease Therapeutics Market - Key Players

Major players operating in the global stargardt disease therapeutics market include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., Hoffmann-La Roche AG, Ocugen, Inc., Ascidian Therapeutics, Nanoscope Therapeutics Inc., Aequus Pharmaceuticals Inc., Fera Pharmaceuticals, LLC, Insmed Incorporated, Belite Bio, Inc., and SpliceBio.